Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

Table 5 Summary of findings table for abacavir-containing cART regimens compared to cART regimens containing zidovudine or stavudine (RCTs)

Outcomes	Illustrative comparative risks* (95 % CI)		Relative effect (95 % CI)	No of Participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	AZT or d4T - containing combination antiretroviral regimens	ABC- containing combination antiretroviral regimens
Virologic suppression - ABC versus d4T (VL < 50–100 copies/ml)	688 per 1000	881 per 1000	RR 1.28	326	⊕ ⊕ ⊕⊝
Follow-up: mean 48 weeks	688 per 1000	(461–1000)	(0.67–2.42	(2 studies)	moderate^a
Adverse events	0 per 1000	0 per 1000	RR 2.41	81	⊕ ⊕ ⊝⊝
Follow-up: mean 48 weeks	0 per 1000	(0–0)	(0.1–57.52)	(1 study)	low^a,b
Death	0 per 1000	0 per 1000	RR 2.41	81	⊕ ⊕ ⊝⊝
Follow-up: mean 48 weeks	0 per 1000	(0–0)	(0.1–57.52)	(1 study)	low^a,b

^a Estimate of effect has a wide conference interval, including both a reduction and increase of effects
^b One study with a small number of participants
* The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

ISSN: 1471-2334